KDR and hydrops fetalis: Meta-analysis of trials of VEGFR-TKIs (sunitinib, sorafenib, pazopanib, axitinib, vandetanib, cabozantinib, ponatinib and regorafenib) including 10,647 patients demonstrated a pooled incidence of asymptomatic HF of 2.4% and symptomatic HF of 1.2%.